SiRNA-based delivery nanoplatform attenuates the CRC progression via HIF1α-AS2

Qingtao Meng(Wuhan University), Rui Chen(Capital Medical University), Hongbao Yang(China Pharmaceutical University), Jin Xu(Nanjing Medical University), Jie Xu(Hubei University of Medicine), Bo Jiang(Capital Medical University), Xiaobo Li(Shanxi Medical University), Jing Wang(NYU Langone Health), Yu Zhang(Rutherford Appleton Laboratory), Xinwei Zhang(Southeast University), Hanqing Chen(Capital Medical University), Na Gao(University of Chinese Academy of Sciences), Shenshen Wu(China Medical University), Yuanyuan Cao(Capital Medical University)
Nano Today
November 9, 2022
Cited by 10


Related Papers